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Objectives of this study were to adapt a commercial human protein C (PC) colorimetric assay for use in dogs and to investigate
eﬀects of various storage conditions. The human assay was modiﬁed by using pooled canine plasma for calibration and by
increasingthe activationtime.PCactivity wasmeasured infresh canineplasmaandinplasmastored under various conditions.PC
activity ofsomestored samples wassigniﬁcantlydiﬀerent from that of fresh plasma;however, diﬀerences were small.No diﬀerence
wasdetected insamplesstoredundersimilarconditionsbutanalyzedindiﬀerentlaboratoriesusingsimilarmethodology.Resultsof
this study indicate that the humancolorimetric assayis suitable for canine samples if pooled canine plasma is used for calibration,
that Clinical and Laboratory Standards Institute sample storage guidelines developed for testing in humans are appropriate for
dogs, and that comparisonsof results from laboratories using similarmethodology are legitimate.
1.Introduction
Protein C is a vitamin K-dependent glycoprotein that is
primarily synthesized in the liver [1]. It circulates in plasma
as a zymogen of a serine protease and is activated by
thrombin-thrombomodulin complex [2]. Activated protein
Ce x e r t sa n t i t h r o m b o t i ce ﬀects by inactivating coagulation
factors Va and VIIIa; additionally, it is reported to have pro-
ﬁbrinolytic,anti-inﬂammatory, and antiapoptoticproperties
[2]. Many conditions are recognized to cause decreased
protein C activity in people, including liver disease, sepsis,
and inﬂammation [2, 3]. In dogs, protein C activity is
decreased with a variety of hepatobiliary diseases, especially
hepatic failure and congenital portosystemic shunts, and has
been used to diﬀerentiate congenital portosystemic shunts
from microvascular dysplasia secondary to portal hypoplasia
[4–6]. Protein C activity is also decreased in dogs with sepsis,
congestive heart failure, and naturally acquired food-borne
aﬂatoxicosis [7–10].
A canine-speciﬁc protein C assay is not commercially
available; therefore, protein C activity in dogs is measured
with human assays that employ colorimetric or clotting
principles. Several reports cite the use of pooled canine
plasma for assay calibration, instead of a commercial human
standard; these studies have been performed using various
combinations of instruments and assay reagents, including
clotting-based and colorimetric (chromogenic substrate-
based) assays [4, 6, 8, 9, 11]. Other reported variations in
methodology include diﬀerent activation times, anticoagu-
lant concentrations, and centrifugation settings for separat-
ing plasma [8, 11, 12]. However, detailed descriptions of test
methodology for measuring protein C concentration in dogs
are scarce. The most detailed explanation of modiﬁcation
of a human assay for dogs [11] describes a clotting-based
assay [11]. However, most studies of protein C activity in
dogs report the use of a colorimetric assay. In adapting a
commercially available human colorimetric protein C assay
(STA-Stachrom protein C colorimetric assay, Diagnostica2 Veterinary Medicine International
Stago, Asnieres, France) for use in dogs by using canine
plasma for calibration, an apparently critical step is the
dilution of the plasma to be used as the 100% standard—
yet this information is not, to our knowledge, anywhere in
the veterinary literature. An accurate, complete description
of how this assay can be adapted for use in dogs would be
of beneﬁt to any veterinary laboratory interested in adding a
protein C assay to its list of test oﬀerings.
Since few veterinary laboratories currently oﬀer protein
C assays, most veterinarians must ship samples in order
to obtain results. According to Clinical and Laboratory
Standards Institute (CLSI) guidelines [13] developed for
laboratory testing in people, samples for measurement of
human protein C activity are stable (variation < ±10%) for
24 months when frozen at −74◦Co r−24◦C[ 13]. However,
relatively little has been published on the stability of canine
protein C under diﬀerent time and temperature conditions.
One study [11] found samples to be stable for at least 1 year
at −80◦C, but the sample size was small (n = 3) and no
detailed data was reported [11]. Another study [14]f o u n d
no signiﬁcant diﬀerence in results obtained using plasma
frozen at −41◦C for 12 to 24 days and those obtained using
plasma stored under similar conditions but that underwent
an additional freeze-thaw cycle; that study did not include a
fresh (unfrozen) plasma control group [14].
T h eo b j e c t i v e so ft h i ss t u d yw e r et oa d a p tac o m m e r c i a l
human protein C colorimetric assay for use in dogs, and
thento determine theeﬀectsofvariousstorageconditionson
results. Our hypothesis was that diﬀerent storage conditions
would signiﬁcantly aﬀect results. Secondary objectives were
to compare results from our laboratory with those from
a laboratory in another state, and to establish preliminary
canine protein C reference values for our laboratory.
2.Materialsand Methods
2.1. Animals. The project involved the use of 28 clinically
normal adult dogs owned by faculty, staﬀ, or students. All
liveanimal work was approved in advance by an institutional
animal care and use committee (University of Tennessee,
protocol #1498). Pooled plasma was made using samples
from 15 dogs (median age = 7 years; 9 mixed breed, 6
diﬀerent pure breeds; 9 spayed females, 6 neutered males).
Experimental phases 1 and 2 were done using samples from
13 dogs of varying age (phase 1, range = 3–9 years, median =
8y e a r s ;p h a s e2 ,r a n g e= 3–9 years, median = 6.5 years),
breed, and sex; samples from 2 dogs were included in both
phases.
2.2. Protein C Assay. Samples were analyzed using an auto-
mated instrument (STA Compact), and commercially avail-
able reagents (STA-Stachrom protein C colorimetric assay,
STA-Owren-Koller buﬀer, STA-System Controls) from the
same manufacturer (Diagnostica Stago, Asnieres, France).
The assay involves a 2-step reaction in which one reagent
(puriﬁed Agkistrodon c. contortrix venom) activates protein
C, another reagent is a chromogenic substrate for the
activated enzyme, and the intensity of the resulting color is
measured spectrophotometrically as optical density (OD).
Standard curves were established using either a commer-
cial human standard (STA-Unicalibrator, Diagnostica Stago,
Asniers, France) according to manufacturer’s instructions,
or pooled canine plasma as described below. In the regular
assay procedure, the 110% human standard calibrator is
diluted 1/3, and all test samples are automatically diluted
1/3 (personal communication, Diagnostica Stago technical
support); another veterinary laboratory using the same assay
for canine samples uses a 1/3 dilution of pooled canine
plasma as the 100% standard, and an activation time of
10 minutes instead of the default 5 minutes (personal
communication, Cornell Animal Health Diagnostic Center).
Based on this information, and on our own experience using
the human standard calibrator, we established a canine-
speciﬁc standard curve using the following dilutions of
pooled canine plasma, and a 10-minute activation time
(dilution = protein C activity): 1/3 = 100%, 1/4 = 75%,
1/6 = 50%, 1/10 = 30%, 1/20 = 15%, and pure buﬀer =
0%. To assess precision, two separate curves were generated
in immediate succession on the same day, both run in
duplicate. Using the second of these curves, a plasma
sample from one normal dog was chosen at random and 6
aliquots were measured as part of a single run to determine
intra-assay precision. A new canine-speciﬁc curve generated
one week later (Curve 2) was used for all subsequent
assays.
2.3. Samples Collection and Handling
2.3.1. Pooled Plasma. Blood samples (6mL) were collected
by jugular venipuncture from 15 dogs into 3.2% sodium
citrate anticoagulant (BD Vacutainer, Becton, Dickenson,
and Co., Franklin Lakes NJ). Samples were centrifuged twice
for 120s at 13,700g (StatSpin,StatSpin,Inc., Norwood MA),
then plasma was harvested within 30 minutes of collection,
placed in 2mL screw-cap tubes (Sarstedt, Newton NC),
frozen at −80◦C within 60 minutes of harvesting, and kept
frozen for 12 to 28d. Samples were thawed by letting the
tubes stand at room temperature, and occasionally rolling
them between open palms. Pooled plasma was created from
250μL aliquots of plasma free of gross lipemia or hemolysis;
any remaining plasma was refrozen at −80◦C.
Phase 1. Blood samples were collected from 9 dogs, and
plasma was harvested as described for making pooled
plasma. Each plasma sample was analyzed within 60 minutes
and the remainder was immediately frozen at −80◦C. After 4
days (n = 7) or 7 days (n = 2), the samples were thawed
and divided into 5 aliquots (0.5mL per aliquot). One of
the aliquots was analyzed immediately, and the others were
immediately refrozen under diﬀerent conditions for later
testing (Table 1(a)).
Phase 2. Blood samples were collected from 6 dogs, and
plasma was harvested as described above. Each plasma
sample was divided into 5 aliquots (0.5mL per aliquot). One
of the aliquots was analyzed immediately, and the others
were immediately frozen under diﬀerent conditions for later
testing (Table 1(b)).Veterinary Medicine International 3
Table 1: Plasmastorage conditions for Phase1 (a) and Phase2 (b).
(a)
Sample Storage conditions
Control NA (fresh plasma)
Aliquot 1.1 4d(7dogs)or7d(2dogs)at−80◦C
Aliquot 1.2
4d(7dogs)or7d(2dogs)at−80◦C, then
thawed, refrozen at −20◦C, and shipped with a
cold pack the next day overnight to an
independent laboratoryA; assay performed 2d
after initial thaw from −80◦C
Aliquot 1.3
4d(7dogs)or7d(2dogs)at−80◦C, then
thawed, refrozen at −20◦C, and packaged the next
day identically to Aliquot 1.2 (package kept at
room temperature); assayperformed 2d after
initial thaw from −80◦C
Aliquot 1.4 4d(7dogs)or7d(2dogs)at−80◦C, then thawed
and refrozen at −80◦C for another 4d
Aliquot 1.5 4d(7dogs)or7d(2dogs)at−80◦C, then thawed
and refrozen at −80◦C for another 7d
ACornell University, Animal Health Diagnostic Center.
(b)
Sample Storage conditions
Control NA (fresh plasma)
Aliquot 2.1 7 d at −80◦C
Aliquot 2.2 7 d at −20◦C
Aliquot 2.3 28 d at −80◦C
Aliquot 2.4 28 d at −20◦C
2.4. Statistical Analysis. Precision of the protein C assay
was determined by calculating coeﬃcients of variation
(CV, deﬁned as standard deviation/mean). Results obtained
using diﬀerent types of samples (fresh v. various storage
conditions) were compared using commercial software (SAS
Version 9.2 of the SAS System for Windows, Cary, NC).
Analyses included: Pearson’s correlation, Student’s t-test for
paired comparisons, and repeated measures ANOVA with
Shapiro-Wilk test for normality of residuals and Levene’s
F-test for equal variances. A P-value < .05 was consid-
ered signiﬁcant. For the null hypothesis that there were
no diﬀerences between control samples and treatments, a
Bonferroni correction was employed to adjust for multiple
t-tests (for Phase 1 comparisons, α/n = 0.05/5 = 0.01;
for Phase 2 comparisons, α/n = 0.05/4 = 0.0125). For
the null hypothesis that there were no diﬀerences between
treatments, Tukey’s post-hoc method was used to adjust
for multiple comparisons. Preliminary canine protein C
reference values for our laboratory were based on minimum
and maximum values from the combined control sample
data sets of Phase 1 and Phase 2.
3.Resultsand Discussion
3.1. Protein C Assay. Based on 4 data points per dilution
(2 standard curves, both run in duplicate), the CVs of
OD measurements were < 5% (low CV = 2.0%, high
CV = 4.8%) for each dilution except pure buﬀer; for pure
Table 2: Comparison of standard curves generated 1 week apart,
usingpooled canineplasma(Curves 1and2),andacurvegenerated
using the manufacturer’s standard protocol (Mfr Std). Results for
protein C (PC) activity shown here are hypothetical, calculated by
inserting arbitrary optical density (OD) values into the regression
equations for the curves (Curve 1: c = [1278.276 × d] − 12.397;
Curve 2: c = [1257.324 × d] − 9.60; Mfr Std curve: c = [515.734 ×
d] − 0.608; where c = PC activity and d = OD). Actual instrument
output for Curve 2 is shown in Figure 1.
Protein C activity (%)
OD Curve 1 Curve 2 Mfr Std curve
0.02 13 16 10
0.04 39 41 20
0.06 64 66 30
0.08 90 91 41
0.10 115 116 51
0.12 141 141 61
−10 10 30 50 70 90 110
Concentration (%)
−0.01
−0.002
0.006
0.015
0.023
0.031
0.039
0.047
0.055
0.064
0.072
0.08
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Figure 1: Instrument output for Curve 2. The standard curve was
established using the following dilutions of pooled canine plasma
(dilution = protein C activity): 1/3 = 100%, 1/4 = 75%, 1/6 = 50%,
1/10 = 30%, 1/20 = 15%, and pure buﬀer = 0%.
buﬀer, 3 readings were 0.000 and 1 was 0.001. Based on 6
separate measurements of the same sample as part of a single
assay run, the CV was 1.4%. Standard curves generated 1
week apart were very similar (Table 2); the instrument
output for the second of these curves is shown in Figure 1.
Protein C activity values were consistently much lower using
the commercial human standard instead of pooled canine
plasma to calibrate the assay (data not shown).
Phase 1. Phase 1 results are summarized in Table 3(a).
Correlation for comparisons of fresh samples with
samples stored under the 5 diﬀerent conditions ranged from
r = 0.76 to r = 0.93. Correlations for comparisons of one4 Veterinary Medicine International
Table 3: Protein C activity results of fresh (control) and stored plasma for Phase 1 (a) and Phase 2 (b). Cross symbols indicate results of
comparisonsofcontrolandtreatment groups,andalphabeticalsymbolsindicateresults ofcomparisonsofdiﬀerent treatment groups; results
for groups including the same symbols are not signiﬁcantly diﬀerent.
(a) Protein C Activity (%, mean ± SD).
Control 4–7d, −80◦C 4–7d, −80◦C; thawed,
2d,−20◦C, send-out
4–7d, −80◦C; thawed,
2d,−20◦C, in-house
4–7d, −80◦C;
thawed, 4d, −80◦C
4–7d, −80◦C;
thawed, 7d, −80◦C
95 ± 10† 100 ± 15†,a,b,c 97 ± 14†,b 102 ± 11†,a,b,c 111 ± 16‡,c 105 ± 15‡,a,b,c
(b) Protein C Activity (%, mean ± SD).
Control 7d, −80◦C7 d , −20◦C2 8 d , −80◦C2 8 d , −20◦C
94 ± 12† 94 ± 11†,a 97 ± 11‡,a 88 ± 10‡,b 87 ± 10‡,b
storage condition with other storage conditions ranged from
r = 0.77 to r = 0.98.
Samples stored for 4 to 7d at −80◦C, then thawed and
refrozen at −80◦C for either an additional 4d or 7d, had
signiﬁcantly higher protein C activity than control samples.
Samples frozen for 4 to 7d at −80◦C, then thawed and
refrozen at −20◦C for an additional 2d and measured in-
house, had higher protein C activity than control samples;
this diﬀerence was marginally signiﬁcant (P<. 02).
There was no signiﬁcant diﬀerence in results determined
by two diﬀerent laboratories using samples stored under the
sameconditions(4to7dat −80◦C,thenthawedandrefrozen
at −20◦C for an additional 2d). Samples stored for 4 to
7d at −80◦C, then thawed and refrozen at −20◦Cf o ra n
additional 2d and measured by a laboratory in another state,
hadsigniﬁcantly lowerproteinCactivity thansamplesstored
for 4 to 7d at −80◦C, then thawed and refrozen at −80◦Cf o r
an additional 4d. Samples stored for 4 to 7d at −80◦Ch a d
lower protein C activity than samples stored for 4 to 7d at
−80◦C, thenthawed and refrozen at −80◦C for an additional
4d;thisdiﬀerence was marginally signiﬁcant (P = .0503).
Phase 2. Phase 2 results are summarized in Table 3(b).
Correlation was high (r>. 95) for all comparisons of
fresh samples with samples stored under various conditions,
and for all comparisons of one storage condition with other
storage conditions.
Samples stored for 7d at −20◦C had signiﬁcantly higher
protein C activity, and samples stored for 28d at either
temperature (−20◦Co r−80◦C) had signiﬁcantly lower
protein C activity, than control samples.
Samples stored for 7d had signiﬁcantly higher protein C
activity than samples stored for 28d, irrespective of storage
temperature.
3.2. Preliminary Reference Values. Based on the combined
control sample data sets of Phase 1 and Phase 2, the
minimum and maximum values for protein C activity
were 80% and 115%, respectively. We are using these as
preliminary lower and upper reference limits, respectively, in
our laboratory.
3.3. Discussion. This study was motivated by our desire to
measure canine protein C activity in our laboratory, and
to learn more about eﬀects of diﬀerent storage conditions
on test results. Limitations of the study included relatively
small sample sizes and fragmentation into two experimental
phasestoinvestigatestorageeﬀects.Despitetheselimitations,
we expect this report to be useful to anyone interested in
establishing a canine protein C assay in their own laboratory
or seeking more information about eﬀects of diﬀerent
storage conditions (including shipping samples to another
institution for analysis).
In our laboratory, the human standard for assay cali-
bration had unacceptably low results (Table 2), similar to
what has been reported by others [11]. This phenomenon
may occur because the protein C-activating reagent, a
highly puriﬁed extract of the venom of the Agkistrodon
c. contortrix snake, does not work as eﬀectively on the
canine protein. Investigators evaluating eﬀects of a similar
extract using a clotting-based assay found canine samples
to be markedly hyporesponsive compared to samples from
humans, cattle, and horses [15]; the precise reason for this
diminished eﬀect is not clear, but the canine protein C
is only partially homologous (72%) with the human form
[15]. Nevertheless, our ﬁndings and those of others indicate
that Agkistrodon c. contortrix venom works suﬃciently on
canine samples to enable the measurement of protein C
activity if pooled canine plasma is used to calibrate the assay.
Using this approach, our preliminary reference values of 80–
115%, based on minimum and maximum values because
of the relatively small sample size, are consistent with those
reported by Toulza et al. (75–135%)[4] and Bauer et al. (76–
119%) [4, 11]. The precision of the assay was acceptable: our
coeﬃcients of variation were lower than reported by others
[4, 8, 11] and met the performance goals for diagnostic
application in humans [4, 8, 11, 16].
We investigated eﬀects of storage conditions diﬀerent
from those previously reported. In one previous study,
plasma samples werestored at −20◦Cfor2monthsor −60◦C
for 10months before analysis [15]. In another study, samples
were stored for a maximum of 3 weeks at −80◦C, although
the analysis of aliquots of 3 specimens also stored for 13
months at −80◦C found no change in results [11]. In a
third study, canine plasma was stored up to 2 months at
−70◦C before batches of samples were shipped to an outside
laboratory for analysis [8]. We used conventional statistical
methods to test for signiﬁcant diﬀerences in protein C
activity. Other investigators [17, 18]h a v ed e ﬁ n e ds t a b i l i t yVeterinary Medicine International 5
of the analyte as a change of <±10% from the initial value
[17, 18]. Using either approach to our data, the protein
Ca c t i v i t yo fs o m es t o r e ds a m p l e sw a sd i ﬀerent from that
of fresh plasma. In addition, some diﬀerences were not
statistically signiﬁcant but had low P-values, suggesting
that the lack of signiﬁcance could be due to small sample
size. However, the mean values for all treatment groups
were within the reference limits and the diﬀerences, even
when statistically signiﬁcant, were small; moreover, only
samples that underwent two freeze-thaw cycles exceeded
10% variation, and then only marginally.
Based on these ﬁndings, we interpret the diﬀerences in
resultsaftertheexperimental storageconditionstobeoflittle
to no clinical signiﬁcance. This interpretation is consistent
with the ﬁndings of investigators who have studied the
eﬀects of diﬀerent storage conditions on human or canine
protein C activity [11, 14, 17–20]. Clinical and Laboratory
Standards Institute guidelines [13] developed for laboratory
testinginpeopleindicatethatspecimens forproteinCtesting
should be kept at room temperature and centrifuged and
tested within 4h from time of collection, or, if testing is not
completed within 4 hours, platelet-poor plasma should be
frozen at −20◦C for up to 2 weeks or at −70◦C for long-
term storage [13]. Based on our results and those of others,
we believe the CLSI sample storage guidelines developed
for testing in humans are also appropriate for testing in
dogs. The CLSI guidelines do not include any speciﬁc
recommendations regarding eﬀects of repeated freeze-thaw
cycleson proteinC activity. Our recommendation is to avoid
repeated freeze-thaw cycles, unless future work addressing
this issue more deﬁnitively indicates otherwise.
Protein C activity was not signiﬁcantly diﬀerent in
samples stored under similar conditions but analyzed in
diﬀerent laboratories. The two laboratories in this study
used the same instruments and assays but diﬀerent batches
of pooled canine plasma to calibrate the assay. The lack
of signiﬁcant diﬀerence suggests that data generated from
laboratories using essentially the same methodology can be
legitimately compared. Variability in protein C resultswithin
and between laboratories has been the subject of study in
human laboratories but, to our knowledge, not in veterinary
laboratories [21].
4.Conclusions
In summary, this report describes how we adapted a com-
mercial human colorimetric protein C assay for use in dogs.
Our preliminary reference values are consistent with those
of other investigators using colorimetric or clotting-based
assays, and the precision of the assay compared favorably
with other reports and with performance goals established
for human laboratories. In addition, we report the eﬀects
of previously unreported storage conditions on test results.
We believe that the diﬀerences between fresh samples and
those stored under the study conditions were of little to
no clinical signiﬁcance, that CLSI guidelines developed for
testing in humans are also appropriate for dogs, and that
comparisonsofresultsfromlaboratoriesusingessentially the
same methodology are likely to be valid.
Acknowledgments
This work was supported in part by the UTCVM Center
of Excellence Summer Student Research Program, and
the UTCVM Angel Fund for Research and Treatment of
Congenital Portosystemic Shunts in Dogs.
References
[1] W. C. Aird, “Natural anticoagulant inhibitors: activated
Protein C,” Best Practice and Research—Clinical Haematology,
vol. 17, no. 1, pp. 161–182, 2004.
[2] S. Danese, S. Vetrano, L. Zhang, V. A. Poplis, and F. J.
Castellino,“TheproteinCpathwayintissueinﬂammationand
injury: pathogenic role and therapeutic implications,” Blood,
vol. 115, no. 6, pp. 1121–1130, 2010.
[3] K. Kottke-Marchant and P. Comp, “Laboratory issues in
diagnosingabnormalities of protein C, thrombomodulin,and
endothelial cell protein C receptor,” Archives of Pathology and
Laboratory Medicine, vol. 126, no. 11, pp. 1337–1348, 2002.
[ 4 ]O .T o u l z a ,S .A .C e n t e r ,M .B .B r o o k s ,H .N .E r b ,K .L .
Warner, andW. Deal, “Evaluationofplasma protein C activity
for detection of hepatobiliary disease and portosystemic
shunting in dogs,” Journal of the American Veterinary Medical
Association, vol. 229, no. 11, pp. 1761–1771, 2006.
[ 5 ]R .M i s c h k e ,D .P ¨ o h l e ,H .A .S c h o o n ,M .F e h r ,a n dI .N o l t e ,
“Alterations of hemostasis in liver cirrhosis of the dog,”
Deutsche Tierarztliche Wochenschrift, vol. 105, no. 2, pp. 43–
47, 1998.
[6] M. Prins, C. Schellens, M. van Leeuwen, J. Rothuizen, and E.
Teske, “Coagulation disorders in dogs with hepatic disease,”
Veterinary Journal, vol. 185, no. 2, pp. 163–168, 2010.
[7] I. Tarnow, T. Falk, A. Tidholm et al., “Hemostatic biomarkers
in dogs with chronic congestive heart failure,” Journal of
Veterinary Internal Medicine,vol.21, no. 3, pp. 451–457,2007.
[ 8 ]A .M .d eL a f o r c a d e ,L .M .F r e e m a n ,S .P .S h a w ,M .B .B r o o k s ,
E. A. Rozanski, and J. E. Rush, “Hemostatic changes in dogs
with naturally occurring sepsis,” Journal of Veterinary Internal
Medicine, vol. 17, no. 5, pp. 674–679, 2003.
[ 9 ]A .d eL a f o r c a d e ,E .A .R o z a n s k i ,L .M .F r e e m a n ,a n dW .L i ,
“Serial evaluation of protein C and antithrombin in dogs with
sepsis,” Journal of Veterinary Internal Medicine,v o l .2 2 ,n o .1 ,
pp. 26–30, 2008.
[10] D. M. Dereszynski, S. A. Center, J. F. Randolph et al., “Clinical
and clinicopathologic features of dogs that consumed food-
borne hepatotoxic aﬂatoxins:72cases (2005-2006),”Journal of
the American Veterinary Medical Association, vol. 232, no. 9,
pp. 1329–1337, 2008.
[11] N. Bauer, O. Eralp, and A. Moritz, “Reference intervals and
method optimizationfor variables reﬂecting hypocoagulatory
and hypercoagulatory states in dogs using the STA Compact
automated analyzer,” Journal of Veterinary Diagnostic Investi-
gation, vol. 21, no. 6, pp. 803–814, 2009.
[12] M. B. Brooks, J. L. Catalfamo, H. Brown, P. Ivanova, and J.
Lovaglio, “A hereditary bleeding disorder of dogs caused by a
lack of platelet procoagulant activity,” Blood,v o l .9 9 ,n o .7 ,p p .
2434–2441, 2002.
[ 1 3 ]D .A d c o c k ,D .H o e f n e r ,K .K o t t k e - M a r c h a n t ,R .M a r l a r ,
D. Szamosi, and D. Warunek, “Collection, transport, and
processing of blood specimens for testing plasma-based
coagulation assays and molecular hemostasisassays;approved
guideline,” in CLSI Document H21-A5, Clinical and Labora-
tory Standards Institute, Wayne, Pa, USA, 5th edition, 2008.6 Veterinary Medicine International
[14] P. E. Yaxley, M. W. Beal, L. A. Jutkowitz et al., “Comparative
stability of canine and feline hemostatic proteins in freeze-
thaw-cycled fresh frozen plasma,” Journal of Veterinary Emer-
gency and Critical Care, vol. 20, no. 5, pp. 472–478, 2010.
[15] I. B. Johnstone and C. A. Martin, “Comparative eﬀects of
the human protein C activator, Protac, on the activated
partial thromboplastin clotting times of plasmas, with special
reference to the dog,” Canadian Journal of Veterinary Research,
vol. 64, no. 2, pp. 117–122, 2000.
[16] P. Meijer, F. Haverkate, and C. Kluft, “Performance goals for
the laboratory testing of antithrombin protein C and protein
S,” Thrombosis and Haemostasis, vol. 96, no. 5, pp. 584–589,
2006.
[17] W. Heil, R. Grunewald, M. Amend, and M. Heins, “Inﬂuence
of time and temperature on coagulation analytes in stored
plasma,” Clinical Chemistry and Laboratory Medicine, vol. 36,
no. 7, pp. 459–462, 1998.
[18] B. Woodhams, O. Girardot, M. J. Blanco, G. Colesse, and
Y. Gourmelin, “Stability of coagulation proteins in frozen
plasma,” Blood Coagulation and Fibrinolysis,v o l .1 2 ,n o .4 ,p p .
229–236, 2001.
[ 1 9 ]E .O ’ N e i l l ,J .R o w l e y ,M .H a n s s o n - W i c h e r ,S .M c C a r t e r ,G .
Ragno, and C. R. Valeri, “Eﬀect of 24-hour whole-blood
storage on plasma clotting factors,” Transfusion, vol. 39, no.
5, pp. 488–491, 1999.
[ 2 0 ]C .I a z b i k ,C .G .C o u t o ,T .L .G r a y ,a n dG .K o c i b a ,“ E ﬀect of
storageconditionsonhemostaticparameters ofcanineplasma
obtained for transfusion,” American Journal of Veterinary
Research, vol. 62, no. 5, pp. 734–735, 2001.
[ 2 1 ]P .M e i j e r ,C .K l u f t ,F .H a v e r k a t e ,a n dM .D eM a a t ,“ T h el o n g -
term within- and between-laboratory variability for assay of
antithrombin, and proteins C and S: results derived from
the external quality assessment program for thrombophilia
screening oftheECAT Foundation,”Journal of Thrombosis and
Haemostasis, vol. 1, no. 4, pp. 748–753, 2003.